eptapirone: 5-HT(1A) receptor agonist; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 208928 |
| CHEMBL ID | 2104230 |
| CHEBI ID | 177708 |
| SCHEMBL ID | 678195 |
| MeSH ID | M0296603 |
| Synonym |
|---|
| 4-methyl-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-as-triazine-3,5(2h,4h)-dione. |
| CHEBI:177708 |
| eptapirone |
| 4-methyl-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2,4-triazine-3,5-dione |
| D02576 |
| 179756-85-5 |
| eptapirone (inn) |
| f 11440 |
| L001606 |
| 4-methyl-2-(4-(4-(pyrimidin-2-yl)piperazino)butyl)-2h,4h-1,2,4-triazin-3,5-dione |
| f-11440 |
| 3m824xro8n , |
| f11440 , |
| 4-methyl-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-as-triazine-3,5(2h,4h)-dione |
| unii-3m824xro8n |
| eptapirone [inn] |
| CHEMBL2104230 |
| eptapirone [who-dd] |
| SCHEMBL678195 |
| DTXSID40170857 |
| HY-19946 |
| CS-5539 |
| EX-A1215 |
| AKOS030525233 |
| 179756-58-2 |
| AS-74190 |
| 4-methyl-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2,4-triazine-3,5(2h,4h)-dione |
| ZB0032 |
| Q5384036 |
| FT-0742442 |
| mfcd08690608 |
| 4-methyl-2-(4-(4-(pyrimidin-2-yl)piperazin-1-yl)butyl)-1,2,4-triazine-3,5(2h,4h)-dione |
| BCP30125 |
| f11440; f-11440; f 11440;f-11,440;f11,440;f 11,440 |
| 4-methyl-2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]-1,2,4-triazine-3, 5-dione |
| A919333 |
| AC-36834 |
| eptapirone[inn] |
Eptapirone is a new 5HT(1A) agonist with a greater intrinsic effect than buspirone.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Eptapirone is a new 5HT(1A) agonist with a greater intrinsic effect than buspirone." | ( The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. Adrover, M; Bailey, JE; Nash, J; Nutt, DJ; Rich, AS; Tournoux, A; Wilson, SJ, 2005) | 1.05 |
| Class | Description |
|---|---|
| N-arylpiperazine | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| 5-hydroxytryptamine receptor 1A | Homo sapiens (human) | Ki | 0.1750 | 0.0001 | 0.5326 | 10.0000 | AID1162482 |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.3609 | 10.0000 | AID1162481 |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.2726 | 10.0000 | AID1162481 |
| Alpha-1B adrenergic receptor | Homo sapiens (human) | Ki | 10.0000 | 0.0000 | 0.4713 | 10.0000 | AID1162481 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1162481 | Displacement of [3H]-7-methoxyprazosin from alpha1 adrenergic receptor (unknown origin) by competition binding assay | 2014 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19 | Synthesis and evaluation of arylpiperazines derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine as 5-HT1AR ligands. |
| AID1162482 | Displacement of [3H]8-OH-DPAT from 5HT1AR (unknown origin) by competition binding assay | 2014 | Bioorganic & medicinal chemistry letters, Oct-01, Volume: 24, Issue:19 | Synthesis and evaluation of arylpiperazines derivatives of 3,5-dioxo-(2H,4H)-1,2,4-triazine as 5-HT1AR ligands. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (20.22) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (40.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||